JP2006510659A5 - - Google Patents

Download PDF

Info

Publication number
JP2006510659A5
JP2006510659A5 JP2004558727A JP2004558727A JP2006510659A5 JP 2006510659 A5 JP2006510659 A5 JP 2006510659A5 JP 2004558727 A JP2004558727 A JP 2004558727A JP 2004558727 A JP2004558727 A JP 2004558727A JP 2006510659 A5 JP2006510659 A5 JP 2006510659A5
Authority
JP
Japan
Prior art keywords
lower alkyl
phenyl
group
independently selected
substituted phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2004558727A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006510659A (ja
JP4739760B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/039530 external-priority patent/WO2004052350A2/en
Publication of JP2006510659A publication Critical patent/JP2006510659A/ja
Publication of JP2006510659A5 publication Critical patent/JP2006510659A5/ja
Application granted granted Critical
Publication of JP4739760B2 publication Critical patent/JP4739760B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2004558727A 2002-12-11 2003-12-11 バルビツール酸誘導体を使用する運動障害の治療方法 Expired - Fee Related JP4739760B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43247002P 2002-12-11 2002-12-11
US60/432,470 2002-12-11
PCT/US2003/039530 WO2004052350A2 (en) 2002-12-11 2003-12-11 Method of treating movement disorders using barbituric acid derivatives

Publications (3)

Publication Number Publication Date
JP2006510659A JP2006510659A (ja) 2006-03-30
JP2006510659A5 true JP2006510659A5 (enExample) 2007-02-01
JP4739760B2 JP4739760B2 (ja) 2011-08-03

Family

ID=32507936

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004558727A Expired - Fee Related JP4739760B2 (ja) 2002-12-11 2003-12-11 バルビツール酸誘導体を使用する運動障害の治療方法

Country Status (17)

Country Link
US (3) US7166610B2 (enExample)
EP (2) EP1569627B1 (enExample)
JP (1) JP4739760B2 (enExample)
CN (2) CN100502871C (enExample)
AR (1) AR042444A1 (enExample)
AT (1) ATE413867T1 (enExample)
AU (2) AU2003302897C1 (enExample)
BR (1) BR0317289A (enExample)
CA (1) CA2505335C (enExample)
CL (1) CL2003002588A1 (enExample)
DE (1) DE60324703D1 (enExample)
ES (1) ES2315569T3 (enExample)
IL (1) IL168853A (enExample)
MX (1) MXPA05006271A (enExample)
PT (1) PT1569627E (enExample)
TW (2) TWI334780B (enExample)
WO (1) WO2004052350A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6939873B2 (en) * 2000-07-26 2005-09-06 Taro Pharmaceuticals Industries Limited Non-sedating barbituric acid derivatives
US6756379B2 (en) * 2001-07-26 2004-06-29 Taro Pharmaceutical Industries Ltd. Non-sedating barbiturate compounds as neuroprotective agents
US7683071B2 (en) 2000-07-26 2010-03-23 Taro Pharmaceuticals Industries Ltd. Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid
AR042444A1 (es) 2002-12-11 2005-06-22 Taro Pharmaceuticals Ireland L Metodo para el tratamiento de desordenes del movimiento mediante la utilizacion de acido barbiturico
CA2572797A1 (en) * 2004-07-02 2006-01-12 Daniella Gutman A process for preparing 1-methoxymethyl-5,5-diphenylbarbituric acid
EP1625848A1 (en) * 2004-08-10 2006-02-15 Taro Pharmaceuticals North America, Inc. Composition and method for enhanced delivery of 5,5-diphenyl barbituric acid
WO2008066704A2 (en) * 2006-11-14 2008-06-05 Taro Pharmaceuticals North America, Inc. Method of improving bioavailability for non-sedating barbiturates
WO2013038427A1 (en) * 2011-09-12 2013-03-21 Council Of Scientific & Industrial Research ARYLATED β-DICARBOIMYL COMPOUNDS AND PROCESS FOR THE PREPARATION THEREOF
IT201700059814A1 (it) * 2017-05-31 2018-12-01 Antonio Costantini Vitamina b1 in alte dosi per uso nel trattamento medico di alcune malattie neurodegenerative sporadiche , di origine genetica e delle cefalee primarie
JP7357432B2 (ja) 2017-10-10 2023-10-06 信越化学工業株式会社 Euv用ペリクルフレーム、ペリクル、ペリクル付露光原版、露光方法、及び半導体の製造方法
JP7787991B2 (ja) * 2021-10-29 2025-12-17 ギリアード サイエンシーズ, インコーポレイテッド Cd73化合物

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1960170A (en) * 1934-05-22 Cc - phenylethyl - n -
US2119701A (en) 1934-06-29 1938-06-07 Winthrop Chem Co Inc Alkoxyalkyl mercury nitrogen compounds
US2673205A (en) * 1951-02-13 1954-03-23 Ciba Pharm Prod Inc 3-disubstituted dioxopiperidines and the manufacture thereof
DE946804C (de) 1952-02-28 1956-08-09 Emanuel Merck Ohg Verfahren zur Herstellung von schwefelhaltigen Abkoemmlingen der Barbitursaeure
DE1103339B (de) 1959-02-04 1961-03-30 Chemische Werke Radebeul Veb Verfahren zur Herstellung von in 5-Stellung crotylierten, basisch substituierten Barbitursaeure-derivaten
DE1100639B (de) 1959-03-24 1961-03-02 Chemische Werke Radebeul Veb Verfahren zur Herstellung von basisch substituierten Barbitursaeure-derivaten
GB966098A (en) 1959-11-23 1964-08-06 Sapos Sa Barbiturate derivatives
US3930006A (en) * 1963-04-30 1975-12-30 Aspro Nicholas Ltd Antiparkinsonism compositions and method
US4046894A (en) * 1968-08-05 1977-09-06 Bristol-Myers Company Certain barbituric acid derivatives used as anticonvulsant agents
US3679683A (en) 1970-05-11 1972-07-25 Exxon Research Engineering Co Barbiturate 3-n-methylene phosphates
US3711607A (en) * 1971-03-17 1973-01-16 Kendall & Co N,n -dihalomethyl phenobarbital for the treatment of convulsions
US3919427A (en) * 1972-06-02 1975-11-11 Kendall & Co Therapeutic compositions containing 1-methyl-3-alkoxymethyl-5,5-disubstituted barbituric acid compounds
US3904627A (en) * 1972-06-02 1975-09-09 Kendall & Co 1-methyl-3-alkoxymethyl-5,5-disubstituted barbituric acid compounds
US3900475A (en) * 1972-06-26 1975-08-19 Kendall & Co Certain phenobarbital salts
US3948896A (en) * 1973-02-28 1976-04-06 The Kendall Company N-mono(alkoxymethyl) phenobarbitals, process therefor and therapeutic composition and method containing same
US4060528A (en) * 1975-10-08 1977-11-29 Janssen Pharmaceutica N.V. Aroyl-substituted phenylmalonic acid derivatives
US4029662A (en) * 1976-04-30 1977-06-14 Bristol-Myers Company Method of making barbituric acid derivatives
DE2622981A1 (de) 1976-05-21 1977-12-08 Unisearch Ltd Verfahren zur herstellung von halogenalkylierten verbindungen
US4260769A (en) 1977-04-22 1981-04-07 Interx Research Corporation 5,5-Diphenylhydantoins
EP0103233B1 (en) * 1982-08-31 1987-11-25 Daikin Kogyo Co., Ltd. A method to trap the enolate ion of the malonic acid or its derivatives
IL69722A (en) 1983-09-14 1986-09-30 Taro Pharma Ind Oxopyrimidine derivatives and pharmaceutical compositions containing them
US4631294A (en) * 1985-07-05 1986-12-23 University E.M., Inc. Treatment of cerebral ischemia with dichloroacetate
IT1196500B (it) * 1986-07-16 1988-11-16 Eniricerche Spa Derivati dell'acido malonico e metodi per la loro sintesi
HU196775B (en) * 1986-08-05 1989-01-30 Richter Gedeon Vegyeszet Process for production of morfologically unique new modifications of famotidin and medical compositions containing such substances
US4833148A (en) * 1987-04-09 1989-05-23 Washington University Method of using alkenyl- or alkynyl-substituted thiobarbiturates to reduce neurotoxic injury
US5474990A (en) * 1989-10-20 1995-12-12 Olney; John W. Barbiturates as safening agents in conjunction with NMDA antagonists
DE4028040A1 (de) 1990-09-05 1992-03-12 Chemie Linz Deutschland Verfahren zur n-alkylierung von harnstoffen
US5456851A (en) 1994-04-07 1995-10-10 Johnson & Johnson Consumer Products, Inc. Ketoconazole shampoo containing butylated hydroxytoluene or butylated hydroxyanisole
DE4433764A1 (de) 1994-09-22 1996-03-28 Asta Medica Ag Darreichungsformen enthaltend alpha-Liponsäure, feste Salze von R-Thioctsäure mit verbesserter Freisetzung und Bioverfügbarkeit
DE19504623A1 (de) 1995-02-13 1996-08-14 Bayer Ag Verfahren zur Herstellung von N-substituierten cyclischen Imiden
RU2147584C1 (ru) * 1995-10-27 2000-04-20 Американ Цианамид Компани Способ получения дигалоидазолопиримидинов и способ получения дигидроксиазолопиримидинов
KR100194535B1 (ko) * 1995-12-27 1999-06-15 우종일 아릴 벤조일 우레아 유도체 및 이를 함유하는 농약조성물
EP0949259B1 (en) * 1996-12-26 2001-06-20 Nikken Chemicals Company, Limited N-hydroxyurea derivatives and medicinal compositions containing the same
US5750766A (en) * 1997-03-18 1998-05-12 American Cyanamid Company Process for the preparation of arylmalonates
US5756815A (en) * 1997-03-18 1998-05-26 American Cyanamid Company Process for the preparation arylamalonates
US6093820A (en) * 1997-10-02 2000-07-25 Taro Pharmaceutical Industries Ltd. Method and reagents for N-alkylating ureides
CA2317008C (en) 1997-12-31 2009-01-20 The University Of Kansas Water soluble prodrugs of tertiary amine containing drugs and methods of making thereof
DE69906960T2 (de) * 1998-05-08 2004-01-29 Smithkline Beecham Plc Phenylurea und phenylthio urea derivate
IL139884A0 (en) 1998-05-26 2002-02-10 Natural Drug Sciences Llc N-substituted derivatives of 5-oximinobarbituric acid
US6156925A (en) * 1998-09-25 2000-12-05 American Cyanamid Company Process for the preparation of halogenated phenylmaloates
US7214658B2 (en) * 2004-07-06 2007-05-08 Tact Ip, Llc Method of delivering a TNF antagonist to the brain of a human by perispinal administration without direct intrathecal injection
US6262067B1 (en) * 1999-06-22 2001-07-17 Pfizer Inc. Polymorphs of a crystalline azo-bicyclo 2,2,2 OCT-3-yl amine dihydrochloride and their pharmaceutical compositions
US6281207B1 (en) 1999-09-15 2001-08-28 Reed Richter Treatment of movement disorders by administration of mirtazapine
EE200200274A (et) * 1999-12-01 2003-06-16 Ucb, S.A. Pürrolidiinatseetamiidi derivaadi kasutamine ravimi valmistamiseks, mis on ette nähtud kesknärvisüsteemi häirete ravimiseks, ja farmatseutiline kompositsioon
WO2001052823A2 (en) * 2000-01-20 2001-07-26 Noven Pharmaceuticals, Inc. Compositions to effect the release profile in the transdermal administration of drugs
CA2306170A1 (en) 2000-04-18 2001-10-18 Kenneth Curry Novel amino, carboxy derivatives of barbituric acid
AU2001280778B2 (en) * 2000-07-26 2004-09-02 Taro Pharmaceutical Industries Ltd. Non-sedating barbiturate compounds as neuroprotective agents
US6939873B2 (en) * 2000-07-26 2005-09-06 Taro Pharmaceuticals Industries Limited Non-sedating barbituric acid derivatives
US7683071B2 (en) * 2000-07-26 2010-03-23 Taro Pharmaceuticals Industries Ltd. Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid
US6756379B2 (en) * 2001-07-26 2004-06-29 Taro Pharmaceutical Industries Ltd. Non-sedating barbiturate compounds as neuroprotective agents
CN1291720C (zh) 2002-01-30 2006-12-27 塔罗制药工业有限公司 非镇静性巴比土酸衍生物
AR042444A1 (es) 2002-12-11 2005-06-22 Taro Pharmaceuticals Ireland L Metodo para el tratamiento de desordenes del movimiento mediante la utilizacion de acido barbiturico
CA2572797A1 (en) * 2004-07-02 2006-01-12 Daniella Gutman A process for preparing 1-methoxymethyl-5,5-diphenylbarbituric acid
EP1625848A1 (en) 2004-08-10 2006-02-15 Taro Pharmaceuticals North America, Inc. Composition and method for enhanced delivery of 5,5-diphenyl barbituric acid
WO2008066704A2 (en) * 2006-11-14 2008-06-05 Taro Pharmaceuticals North America, Inc. Method of improving bioavailability for non-sedating barbiturates

Similar Documents

Publication Publication Date Title
JP2006182786A5 (enExample)
JP2006526031A5 (enExample)
JP2005053931A5 (enExample)
EP1857457A3 (en) Benzimidazole derivative and its use as AII receptor antagonist
JP2004137288A5 (enExample)
JP2008501000A5 (enExample)
JP2010530881A5 (enExample)
JP2006151984A5 (enExample)
JP2007508360A5 (enExample)
JP2007510619A5 (enExample)
JP2009502743A5 (enExample)
JP2006522035A5 (enExample)
JP2005539088A5 (enExample)
JP2009504763A5 (enExample)
JP2007508361A5 (enExample)
JP2005511698A5 (enExample)
JP2019516739A5 (enExample)
JP2002527474A5 (ja) 躁病および双極性障害の治療のための医薬
JP2006510659A5 (enExample)
JP2002527414A5 (enExample)
JP2012508251A5 (enExample)
JP2005536503A5 (enExample)
JP2010534246A5 (enExample)
JP2012511558A5 (enExample)
JP2004502684A5 (enExample)